These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 34497204)

  • 1. [Antibody therapy for multiple myeloma].
    Handa H
    Rinsho Ketsueki; 2021; 62(8):1167-1177. PubMed ID: 34497204
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Antibody therapy for multiple myeloma: novel approaches and future perspectives].
    Ishida T
    Rinsho Ketsueki; 2020; 61(8):912-921. PubMed ID: 32908055
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Elotuzumab as a novel anti-myeloma immunotherapy.
    Radhakrishnan SV; Bhardwaj N; Steinbach M; Weidner J; Luetkens T; Atanackovic D
    Hum Vaccin Immunother; 2017 Aug; 13(8):1751-1757. PubMed ID: 28604269
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeting B Cell Maturation Antigen (BCMA) in Multiple Myeloma: Potential Uses of BCMA-Based Immunotherapy.
    Cho SF; Anderson KC; Tai YT
    Front Immunol; 2018; 9():1821. PubMed ID: 30147690
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Current status and future prospects of immunotherapy for multiple myeloma].
    Imai Y
    Rinsho Ketsueki; 2021; 62(5):407-417. PubMed ID: 34108322
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Monoclonal Antibodies for the Treatment of Multiple Myeloma: An Update.
    Abramson HN
    Int J Mol Sci; 2018 Dec; 19(12):. PubMed ID: 30544512
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical and Pharmacologic Features of Monoclonal Antibodies and Checkpoint Blockade Therapy in Multiple Myeloma.
    D'Agostino M; Gazzera G; Cetani G; Bringhen S; Boccadoro M; Gay F
    Curr Med Chem; 2019; 26(32):5968-5981. PubMed ID: 29756564
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immunotherapy in multiple myeloma: when, where, and for who?
    Verkleij CPM; Korst CLBM; van de Donk NWCJ
    Curr Opin Oncol; 2020 Nov; 32(6):664-671. PubMed ID: 32852308
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Update on elotuzumab, a novel anti-SLAMF7 monoclonal antibody for the treatment of multiple myeloma.
    Lonial S; Kaufman J; Reece D; Mateos MV; Laubach J; Richardson P
    Expert Opin Biol Ther; 2016 Oct; 16(10):1291-301. PubMed ID: 27533882
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Mechanism of action and clinical results of immunotherapy for multiple myeloma].
    Imai Y
    Rinsho Ketsueki; 2022; 63(9):1180-1187. PubMed ID: 36198543
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monoclonal antibodies as an addition to current myeloma therapy strategies.
    Jullien M; Touzeau C; Moreau P
    Expert Rev Anticancer Ther; 2021 Jan; 21(1):33-43. PubMed ID: 33052750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunotherapy: A New Approach to Treating Multiple Myeloma with Daratumumab and Elotuzumab.
    Afifi S; Michael A; Lesokhin A
    Ann Pharmacother; 2016 Jul; 50(7):555-68. PubMed ID: 27083916
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Monoclonal Antibodies in Multiple Myeloma: A New Wave of the Future.
    Sherbenou DW; Mark TM; Forsberg P
    Clin Lymphoma Myeloma Leuk; 2017 Sep; 17(9):545-554. PubMed ID: 28734795
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [Combination therapy with monoclonal antibodies for treatment of newly diagnosed multiple myeloma].
    Nishimura N; Terui Y; Hatake K
    Rinsho Ketsueki; 2017; 58(8):1006-1013. PubMed ID: 28883263
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multiple myeloma: Updates for pharmacists in the treatment of relapsed and refractory disease.
    Ashjian E; Redic K
    J Oncol Pharm Pract; 2016 Apr; 22(2):289-302. PubMed ID: 25694345
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma.
    van de Donk NW; Moreau P; Plesner T; Palumbo A; Gay F; Laubach JP; Malavasi F; Avet-Loiseau H; Mateos MV; Sonneveld P; Lokhorst HM; Richardson PG
    Blood; 2016 Feb; 127(6):681-95. PubMed ID: 26631114
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of SLAMF7 in multiple myeloma: impact on therapy.
    Boudreault JS; Touzeau C; Moreau P
    Expert Rev Clin Immunol; 2017 Jan; 13(1):67-75. PubMed ID: 27376202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Advances in targeted therapy for the treatment of patients with relapsed/refractory multiple myeloma.
    Le Ray E; Jagannath S; Palumbo A
    Expert Rev Hematol; 2016 Jan; 9(1):91-105. PubMed ID: 26558304
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Current strategies for treatment of relapsed/refractory multiple myeloma.
    Laubach JP; Voorhees PM; Hassoun H; Jakubowiak A; Lonial S; Richardson PG
    Expert Rev Hematol; 2014 Feb; 7(1):97-111. PubMed ID: 24471924
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of relapsed and refractory multiple myeloma: novel agents, antibodies, immunotherapies and beyond.
    Chim CS; Kumar SK; Orlowski RZ; Cook G; Richardson PG; Gertz MA; Giralt S; Mateos MV; Leleu X; Anderson KC
    Leukemia; 2018 Feb; 32(2):252-262. PubMed ID: 29257139
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.